ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

Slides:

Advertisements

Similar presentations

CLINICAL QUESTION By: Resident Name. 25 y/o male w/ hx of ___, ____, and ____, who presented w/ _______ found to have ________ admitted for ______ and.

Advertisements

Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.

Glucose – Insulin – Potassium Study in Patients with ST Elevation Myocardial Infarction without Signs of Heart Failure Presented at American College of.

Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Randomized, double-blind, multicenter, controlled trial.

Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

Rapid Fire Journal Club May 16, 2014 Sadie T. Velásquez.

Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.

No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion CREATE-ECLA - GIK Trial Presented at: American Heart Association.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure Results of a Veterans Administration Cooperative Study (V-HEFT I) Multicenter,

Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.

Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, Marvin A. Konstam, G. Michael.

CARIN Trial design: Patients undergoing coronary angiography were randomized in a 1:1:1:1 fashion to CMX mg/kg, 3.6 mg/kg, 4.8 mg/kg, or placebo.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Valsartan in Acute Myocardial Infarction Trial Investigators

CLINICAL DILEMMAS IN HEART FAILURE:

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

The Safety and Efficacy of Full vs

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

PROACT-4 Trial design: Patients enroute to the hospital with acute chest pain were randomized to point of care troponin testing (n = 305) vs. usual care.

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

Losartan vs. Atenolol in Marfan Syndrome

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

Biomarker-Guided HF Therapy: Is It Cost-Effective?

% decrease in LDL-C at 24 weeks from baseline

MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo.

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Modified Rankin score 0-2

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

Using Heart Rate as a Biomarker in Clinical Practice.

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

AMISTAD II: Study Design

MK-0954 PN948 NOT APPROVED FOR USE (date)

ALBATROSS Trial design: Patients with MI without heart failure were randomized to an IV bolus of potassium canrenoate 200 mg as early as possible, then.

American Heart Association Presented by Dr. Julinda Mehilli

(p-value between groups = 0.59)

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Ezetimibe/simvastatin

Impedence-guided management

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

Anaerobic threshold responder analysis

(p for noninferiority < 0.001)

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Metoprolol for AR Trial design: Patients with chronic asymptomatic severe aortic regurgitation (AR) were randomized to metoprolol CR/XL 200 mg or matching.

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

STOP-CHAGAS Trial design: Asymptomatic patients with serological evidence of T. cruzi were randomized to posaconazole 400 mg BID, benznidazole 200 mg BID,

Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

HF Definition. Why and How Should We Be Treating Patients With Heart Failure With Preserved Ejection Fraction?

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Key Data on Improving Outcomes in HF Patients

Presentation transcript:

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone (n = 178). Results (p = 0.57) Primary outcome, log change in NT-proBNP at 96 hours: -0.55 in the spironolactone group vs. -0.49 in the placebo group (p = 0.57) Net urine output: 6.1 L in the spironolactone group vs. 5.6 L in the placebo group (p = 0.57) Conclusions Among patients admitted with acute heart failure, high-dose spironolactone was not effective at reducing NT-proBNP levels Secondary outcomes, including urine output, were also similar between treatment groups -0.49 -0.55 Spironolactone Control Presented by Dr. Javed Butler at AHA 2016